Opus Genetics (IRD) Income from Continuing Operations (2010 - 2026)
Opus Genetics (IRD) reported Income from Continuing Operations of 65535000.0 for Q1 2026, down 699.79% year-over-year from 10926278.1 in Q1 2025, and down 296.63% on a QoQ basis from 16523000.0 in Q4 2025.
Opus Genetics (IRD) has 17 years of Income from Continuing Operations data on file, last reported at 65535000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 699.79% year-over-year to 65535000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 106932000.0 (down 82.42% YoY) and the FY2025 annual result came in at 49591000.0, up 13.8% from the prior year.
- Income from Continuing Operations fell to 65535000.0 in Q1 2026 per IRD's latest filing, from 16523000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 33941000.0 in Q4 2022 and bottomed at 65535000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 7106000.0 (2024), against an average of 9691529.41.
- The widest annual swing landed in 2022, when Income from Continuing Operations soared 637.64%; it then slumped 699.79% in 2026.
- Tracing IRD's Income from Continuing Operations over 5 years: stood at 33941000.0 in 2022, then tumbled by 114.13% to 4795000.0 in 2023, then tumbled by 632.74% to 35135000.0 in 2024, then surged by 52.97% to 16523000.0 in 2025, then tumbled by 296.63% to 65535000.0 in 2026.
- Per Business Quant, the three latest IRD Income from Continuing Operations figures stand at 65535000.0 (Q1 2026), 16523000.0 (Q4 2025), and 17454000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | -65.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.54 Mn |
| Dec 31, 2025 | -16.52 Mn |
| Sep 30, 2025 | -17.45 Mn |
| Jun 30, 2025 | -7.42 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -35.14 Mn |
| Sep 30, 2024 | -7.53 Mn |
| Jun 30, 2024 | -7.77 Mn |
| Mar 31, 2024 | -7.11 Mn |
| Dec 31, 2023 | -4.80 Mn |
| Sep 30, 2023 | 5.56 Mn |
| Jun 30, 2023 | -4.96 Mn |
| Mar 31, 2023 | -5.79 Mn |
| Dec 31, 2022 | 33.94 Mn |
| Sep 30, 2022 | -4.53 Mn |
| Jun 30, 2022 | -4.93 Mn |
| Mar 31, 2022 | -6.60 Mn |
| Dec 31, 2021 | -6.31 Mn |
| Sep 30, 2021 | -4.23 Mn |
| Jun 30, 2021 | -7.14 Mn |
| Mar 31, 2021 | -39.01 Mn |
| Dec 31, 2020 | -18.68 Mn |
| Sep 30, 2020 | -1.25 Mn |
| Jun 30, 2020 | -1.60 Mn |
| Mar 31, 2020 | -3.09 Mn |
| Dec 31, 2019 | 597,510.00 |
| Sep 30, 2019 | -1.96 Mn |
| Jun 30, 2019 | -2.46 Mn |
| Mar 31, 2019 | -2.34 Mn |
| Dec 31, 2018 | -3.12 Mn |
| Sep 30, 2018 | -5.34 Mn |
| Jun 30, 2018 | -3.84 Mn |
| Mar 31, 2018 | -2.07 Mn |
| Dec 31, 2017 | -3.59 Mn |
| Sep 30, 2017 | -1.04 Mn |
| Jun 30, 2017 | 947,056.00 |
| Mar 31, 2017 | -21.61 Mn |
| Dec 31, 2016 | -525,483.00 |
| Sep 30, 2016 | -2.87 Mn |
| Jun 30, 2016 | -1.77 Mn |
| Mar 31, 2016 | -4.15 Mn |
| Dec 31, 2015 | -2.85 Mn |
| Sep 30, 2015 | -4.03 Mn |
| Jun 30, 2015 | -3.23 Mn |
| Mar 31, 2015 | -4.27 Mn |
| Dec 31, 2014 | -2.21 Mn |
| Sep 30, 2014 | -1.91 Mn |
| Jun 30, 2014 | 194,464.00 |
| Mar 31, 2014 | -14.60 Mn |
| Dec 31, 2013 | -2.72 Mn |
| Sep 30, 2013 | -2.14 Mn |
| Jun 30, 2013 | -3.11 Mn |
| Mar 31, 2013 | -1.53 Mn |
| Dec 31, 2012 | -55,404.00 |
| Sep 30, 2012 | -2.99 Mn |
| Jun 30, 2012 | -1.04 Mn |
| Mar 31, 2012 | -2.14 Mn |
| Dec 31, 2011 | 389,281.00 |
| Sep 30, 2011 | -1.47 Mn |
| Jun 30, 2011 | -5.83 Mn |
| Mar 31, 2011 | -4.44 Mn |
| Dec 31, 2010 | -2.61 Mn |
| Sep 30, 2010 | 218,891.00 |
| Jun 30, 2010 | -3.60 Mn |